Last reviewed · How we verify
Mygliol Oil
Mygliol Oil is a medium-chain triglyceride (MCT) formulation designed to improve drug solubility and bioavailability when used as a pharmaceutical excipient or delivery vehicle.
At a glance
| Generic name | Mygliol Oil |
|---|---|
| Sponsor | University of Dundee |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Mygliol Oil consists of medium-chain fatty acids (typically C8-C10) that enhance the dissolution and absorption of poorly soluble drugs. It functions as a lipid-based formulation excipient that can increase drug permeability across the gastrointestinal tract and improve lymphatic transport, thereby enhancing oral bioavailability of lipophilic compounds.
Approved indications
Common side effects
Key clinical trials
- Effect of Omega 3 in Hypertensive Patients (NA)
- Can Vitamin D Supplementation Improve Hepatitis C Cure Rates (PHASE3)
- Nutritional Therapy of the Deficits of Oxidation Mitochondrial of the Fatty Acids (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mygliol Oil CI brief — competitive landscape report
- Mygliol Oil updates RSS · CI watch RSS
- University of Dundee portfolio CI